SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics , the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TSRA-196, its lead in vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD). The Company has also received Australian Human Research Ethics Committee (HREC) approval